Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion type Assertion NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_head.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion description "[We have evaluated the activity of purified human recombinant soluble TRAIL (S-TRAIL, comprising residues 114-281; Biomol, Plymouth Meeting, PA, USA) and a leucine zipper construct of TRAIL (LZ-TRAIL; Immunex, Seattle WA, USA) against myeloma cell lines NCI H929, U266, RPMI 8226, the FasL-sensitive Jurkat T cell ALL line, the lymphoblastoid cell line MC/CAR and primary tumour cells from 16 myeloma patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_provenance.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion evidence source_evidence_literature NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_provenance.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion SIO_000772 11587225 NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_provenance.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion wasDerivedFrom befree-20140225 NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_provenance.
- NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_assertion wasGeneratedBy ECO_0000203 NP493564.RA2rOaHV70peabm1fQjttDQN1TCaOedtt3hz0WwQxhCUg130_provenance.